Okay, there is a lot of talk about patients needing more frequent b12 injections. There is also a lot of talk that there is not enough evidence to prove the same.
There is a way around this:
Pharmaceutical companies are responsible for the efficiency of their products. Both doctors and patients can report issues with products.
Pharma companies have to record these and act accordingly.
I have direct experience of being one of those that reported issues with another product and subsquently, and quite quickly, the product directions were changed.
Most people think of issues with products being related to side effects - although this is an, obviously important issue, it should also be reported if the product is not being as effective as it should be. Meaning the pharma companies have to re-visit their research and guidelines.
When it comes to b12 in the UK you will find on b12 product data sheets that the guidelines referring to 3 monthly jabs are in respect of treating anaemia only. For many b12 deficient patients they never get the anaemia and the neurological symptoms and permanent damage long precede anaemia. Yet the product does not refer to this. It should.
Doctors should be reporting that patients are having returning neuro symptoms with injections at the current rate, but they are not. However patients can report it. This, in effect, makes the pharmaceutical company responsible for any patient suffering neurological damage who has reported their product is not effective.
To do this, ask for your prescription record. On their (there - I found the edit button) it should give the name of the product (B12) you are being given. Look up the data sheet on the internet and locate the producing company. Telephone the company, explain your neuro symptoms come back. They may state that their product is only for treating anaemia. Tell them you still want the problems recording and that you would like a reference number.
If enough people do this, and with pharmaceutical companies it doesn't take many, then they have to start instigating change. Class actions don't appeal to them much.